{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T08:58:23Z","timestamp":1793350703176,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-40757-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T21:55:14Z","timestamp":1773266114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety signals from early-phase studies of KRAS inhibition in pancreatic cancer"],"prefix":"10.1038","volume":"16","author":[{"given":"Kathlen Oliveira Martins","family":"Tiede","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Fernanda","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ohana","family":"Chiaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Moura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad Bassam","family":"Sonbol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitesh","family":"Borad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanios","family":"Bekaii-Saab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Luiz Serrano Uson","family":"Junior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"40757_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L. et al. CA Cancer J. Clin. 75(1), 10\u201345. https:\/\/doi.org\/10.3322\/caac.21871 (2025).","DOI":"10.3322\/caac.21871"},{"issue":"19","key":"40757_CR2","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy, T. et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N. Engl. J. Med. 364 (19), 1817\u20131825. https:\/\/doi.org\/10.1056\/NEJMoa1011923 (2011).","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"40757_CR3","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DDV Hoff","year":"2013","unstructured":"Hoff, D. D. V. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N. Engl. J. Med. 369 (18), 1691\u20131703. https:\/\/doi.org\/10.1056\/NEJMoa1304369 (2013).","journal-title":"N. Engl. J. Med."},{"key":"40757_CR4","doi-asserted-by":"publisher","unstructured":"Goldstein, D. et al. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial. J. Natl. Cancer Inst. 107 (2). https:\/\/doi.org\/10.1093\/jnci\/dju413 (2015).","DOI":"10.1093\/jnci\/dju413"},{"issue":"27","key":"40757_CR5","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1200\/jco.20.01364","volume":"38","author":"DPS Sohal","year":"2020","unstructured":"Sohal, D. P. S. et al. Metastatic pancreatic cancer: ASCO guideline update. J. Clin. Oncol. 38 (27), 3217\u20133230. https:\/\/doi.org\/10.1200\/jco.20.01364 (2020).","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"40757_CR6","first-page":"318","volume":"63","author":"CL Wolfgang","year":"2013","unstructured":"Wolfgang, C. L. et al. Recent progress in pancreatic cancer. CA Cancer J. Clin. 63 (5), 318\u2013348 (2013).","journal-title":"CA Cancer J. Clin."},{"key":"40757_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2147\/ceg.s390655","volume":"17","author":"R Imperial","year":"2024","unstructured":"Imperial, R. et al. Second-line treatment of pancreatic adenocarcinoma: Shedding light on new opportunities and key talking points from clinical trials. Clin. Exp. Gastroenterol. 17, 121\u2013134. https:\/\/doi.org\/10.2147\/ceg.s390655 (2024).","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"7477","key":"40757_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A. & Shokat, K. M. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503 (7477), 548\u2013551. https:\/\/doi.org\/10.1038\/nature12796 (2013).","journal-title":"Nature"},{"issue":"1","key":"40757_CR9","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa2208470","volume":"388","author":"JH Strickler","year":"2023","unstructured":"Strickler, J. H. et al. Sotorasib in <\u2009i>KRAS p.G12C-mutated advanced pancreatic cancer. N. Engl. J. Med. 388 (1), 33\u201343. https:\/\/doi.org\/10.1056\/NEJMoa2208470 (2023).","journal-title":"N. Engl. J. Med."},{"key":"40757_CR10","doi-asserted-by":"publisher","unstructured":"Papke, B., Der, C. J. & Drugging, R. A. S. Know the enemy. Science. 355(6330), 1158\u20131163. https:\/\/doi.org\/10.1126\/science.aam7622 (2017).","DOI":"10.1126\/science.aam7622"},{"issue":"7","key":"40757_CR11","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1016\/j.ccell.2024.06.005","volume":"42","author":"AA Flores-G\u00f3mez","year":"2024","unstructured":"Flores-G\u00f3mez, A. A. & Drosten, M. HRS-4642: The next piece of the puzzle to keep KRAS in check. Cancer Cell. 42 (7), 1157\u20131159. https:\/\/doi.org\/10.1016\/j.ccell.2024.06.005 (2024).","journal-title":"Cancer Cell."},{"issue":"4_suppl","key":"40757_CR12","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1200\/JCO.2025.43.4_suppl.724","volume":"43","author":"AI Spira","year":"2025","unstructured":"Spira, A. I. et al. Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal adenocarcinoma (PDAC) from a phase 1 study in advanced solid tumors. J. Clin. Oncol. 43 (4_suppl), 724. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.724 (2025).","journal-title":"J. Clin. Oncol."},{"key":"40757_CR13","doi-asserted-by":"publisher","first-page":"S458","DOI":"10.1016\/j.annonc.2023.09.1838","volume":"34","author":"KC Arbour","year":"2023","unstructured":"Arbour, K. C. et al. 652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC). Ann. Oncol. 34, S458. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1838 (2023).","journal-title":"Ann. Oncol."},{"issue":"4_suppl","key":"40757_CR14","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1200\/JCO.2025.43.4_suppl.722","volume":"43","author":"I Garrido-Laguna","year":"2025","unstructured":"Garrido-Laguna, I. et al. Safety, efficacy, and on-treatment circulating tumor DNA (ctDNA) changes from a phase 1 study of RMC-6236, a RAS(ON) multi-selective, tri-complex inhibitor, in patients with RAS mutant pancreatic ductal adenocarcinoma (PDAC). J. Clin. Oncol. 43 (4_suppl), 722. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.722 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"16_suppl","key":"40757_CR15","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1200\/JCO.2025.43.16_suppl.3013","volume":"43","author":"X Ai","year":"2025","unstructured":"Ai, X. et al. A first-in-human phase I\/II study of GFH375, a highly selective and potent oral KRAS G12D inhibitor in patients with KRAS G12D mutant advanced solid tumors. J. Clin. Oncol. 43 (16_suppl), 3013. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3013 (2025).","journal-title":"J. Clin. Oncol."},{"issue":"13","key":"40757_CR16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong, D. S. et al. KRAS\u2009<\u2009sup>G12C Inhibition with sotorasib in advanced solid tumors. N. Engl. J. Med. 383 (13), 1207\u20131217. https:\/\/doi.org\/10.1056\/NEJMoa1917239 (2020).","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"40757_CR17","doi-asserted-by":"publisher","first-page":"4097","DOI":"10.1200\/jco.23.00434","volume":"41","author":"TS Bekaii-Saab","year":"2023","unstructured":"Bekaii-Saab, T. S. et al. Adagrasib in advanced solid tumors harboring a KRAS(G12C) mutation. J. Clin. Oncol. 41 (25), 4097\u20134106. https:\/\/doi.org\/10.1200\/jco.23.00434 (2023).","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"40757_CR18","doi-asserted-by":"publisher","first-page":"R921","DOI":"10.1016\/j.cub.2020.06","volume":"30","author":"NM Anderson","year":"2020","unstructured":"Anderson, N. M. & Simon, M. C. The tumor microenvironment. Curr. Biol. 30 (16), R921\u2013r5. https:\/\/doi.org\/10.1016\/j.cub.2020.06.081 (2020).","journal-title":"Curr. Biol."},{"issue":"7","key":"40757_CR19","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1158\/2159-8290.cd-25-0349","volume":"15","author":"RY Ebright","year":"2025","unstructured":"Ebright, R. Y., Dilly, J., Shaw, A. T. & Aguirre, A. J. Response and resistance to RAS inhibition in cancer. Cancer Discov. 15 (7), 1325\u20131349. https:\/\/doi.org\/10.1158\/2159-8290.cd-25-0349 (2025).","journal-title":"Cancer Discov"},{"key":"40757_CR20","doi-asserted-by":"publisher","first-page":"S597","DOI":"10.1016\/j.annonc.2025.08.1485","volume":"36","author":"J Desai","year":"2025","unstructured":"Desai, J. et al. 916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors. Ann. Oncol. 36, S597\u2013S8. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1485 (2025).","journal-title":"Ann. Oncol."},{"key":"40757_CR21","doi-asserted-by":"publisher","first-page":"S596","DOI":"10.1016\/j.annonc.2025.08.1484","volume":"36","author":"A Xiong","year":"2025","unstructured":"Xiong, A. et al. 915O KRAS G12D inhibitor HRS-4642 in patients with KRAS G12D-mutant advanced solid tumors: A phase I trial. Ann. Oncol. 36, S596\u2013S7. https:\/\/doi.org\/10.1016\/j.annonc.2025.08.1484 (2025).","journal-title":"Ann. Oncol."},{"key":"40757_CR22","doi-asserted-by":"publisher","first-page":"S1741","DOI":"10.1016\/j.annonc.2025.09.099","volume":"36","author":"A Zhou","year":"2025","unstructured":"Zhou, A. et al. LBA84 Efficacy and safety of GFH375 monotherapy in previously treated advanced KRAS G12D-mutant pancreatic ductal adenocarcinoma (PDAC). Ann. Oncol. 36, S1741. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.099 (2025).","journal-title":"Ann. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40757-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40757-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:05:09Z","timestamp":1776899109000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-40757-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["40757"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-40757-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M.B.S. declares the following: Novartis (consulting for self), Boehringer Ingelheim (consulting for institution), Bayer (consulting for institution), Eli Lilly, and Taiho (research support for institution). All other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13189"}}